Positive News SentimentPositive NewsNASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis $1.81 -0.05 (-2.69%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Entera Bio Stock (NASDAQ:ENTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entera Bio alerts:Sign Up Key Stats Today's Range$1.80▼$1.8650-Day Range$1.65▼$2.1252-Week Range$0.52▼$3.35Volume10,630 shsAverage Volume119,944 shsMarket Capitalization$64.77 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Entera Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks59th Percentile Overall ScoreENTX MarketRank™: Entera Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 505th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntera Bio has only been the subject of 1 research reports in the past 90 days.Read more about Entera Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.23) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Entera Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.11% of the outstanding shares of Entera Bio have been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 14.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.11% of the outstanding shares of Entera Bio have been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 14.41%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment1.58 News SentimentEntera Bio has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entera Bio this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock News HeadlinesBuy Rating Affirmed for Entera Bio’s EB613: A Game Changer in Osteoporosis TreatmentOctober 8, 2024 | markets.businessinsider.comEntera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic DisordersSeptember 25, 2024 | globenewswire.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Quantum Genomics Société Anonyme (2QG.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comWe're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn RateAugust 30, 2024 | finance.yahoo.comEntera Bio to Participate in Upcoming Investor and Scientific ConferencesAugust 20, 2024 | globenewswire.comEntera Bio Receives Strong Buy Rating Amid Anticipated FDA Ruling and Pipeline ProgressAugust 12, 2024 | markets.businessinsider.comEntera Bio Ltd.: Entera Bio Reports Q2 2024 Financial Results and Provides Business UpdatesAugust 11, 2024 | finanznachrichten.deSee More Headlines ENTX Stock Analysis - Frequently Asked Questions How have ENTX shares performed this year? Entera Bio's stock was trading at $0.60 on January 1st, 2024. Since then, ENTX stock has increased by 201.7% and is now trading at $1.81. View the best growth stocks for 2024 here. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $0.06 million for the quarter. When did Entera Bio IPO? Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and General Electric (GE). Company Calendar Last Earnings8/09/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+452.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax Margin-14,924.56% Return on Equity-100.37% Return on Assets-84.09% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$57,000.00 Price / Sales1,136.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book5.03Miscellaneous Outstanding Shares35,785,000Free Float31,884,000Market Cap$64.77 million OptionableOptionable Beta1.57 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:ENTX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.